Safest timing of pegfilgrastim administration seems to be 72 hours after chemo
the ONA take:
For the prevention of leukocytosis, the safest timing of pegfilgrastim administration based on white blood cell (WBC) count in patients receiving dose-dense anthracycline- and taxane-based regimens seems to be 72 hours following chemotherapy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers sought to determine the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy.
Researchers enrolled 41 patients and assigned them to receive pegfilgrastim 24 hours, 72 hours, or 96 hours after chemotherapy. Safety was determined by the occurrence of early and late leukocytosis and the behavior of WBCs.
Results showed that the occurrence of early leukocytosis was more common in the 24-hour cohort, while late leukocytosis occurred most frequently in the 96-hour cohort.
Researchers found that patients in the 24-hour group experienced the highest median value of WBC count 24 hours after pegfilgrastim administrated and those in the 96-hour group experienced the highest median value at day 13 in both chemotherapy cycles.
Safest timing of pegfilgrastim administration based on white blood cell count seems to be 72 hours following chemotherapy.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|